MARIA SOULI, MD, PhD
1. Personal Information
Date of Birth: June 14, 1964
Tel: +30 210 9329519
Email: msouli@med.uoa.gr
Specialty: Internal Medicine-Infectious Diseases
Current Position: Assistant Professor, Athens University School of Medicine,
4th Dpt of Internal Medicine, University General Hospital “Attikon”
2. Degrees
1988 Bachelor of Medicine, Athens University School of Medicine
1996 PhD Degree, Athens University School of Medicine
1996 Title, Medical Specialty in Internal Medicine
2000 Title, Medical Specialty in Infectious Diseases
2005 to 2009: Lecturer in Internal Medicine and Infectious Diseases, Athens
University School of Medicine
2009 to present: Assistant Professor in Internal Medicine and Infectious
Diseases, Athens University School of Medicine
3. Clinical Experience
December 1988 to December 1989:
Medical Doctor providing compulsory Rural Service- Naxos, Greece
January 1990 to June 1996:
Assistant, Infectious Diseases Outpatient Clinic, First Dpt of Propedeutic
Medicine, “Laikon” General Hospital, Athens University School of Medicine
January 1990 to June 1996:
Research Associate, Infectious Diseases Laboratory, First Dpt of Propedeutic
Medicine, “Laikon” General Hospital, Athens University School of Medicine
February 1991 to February 1996:
Resident in Internal Medicine, First Dpt of Propedeutic Medicine, “Laikon”
General Hospital, Athens University School of Medicine
July 1996 to October 1998:
Research Fellow in Infectious Diseases at Beth Israel Deaconess Medical
Center West Campus, Harvard Medical School, Boston, USA
September 1998-July 2000:
Infectious Diseases Associate, 4th Dpt of Internal Medicine, “Sismanoglion”
General Hospital, Athens, Greece
Main responsibilities: Participating in the program for the surveillance,
prevention and control of health-care associated infections, Attending
Physician in Infectious Diseases Outpatient Clinic, Infectious Diseases
Consultant for hospitalised patients, Participating in various research
programs in the field of Infectious Diseases and Antimicrobial Resistance
July 2000-February 2005:
Attending Physician, 4th Dpt of Internal Medicine, “Sismanoglion” General
Hospital, Athens, Greece
Main responsibilities: Attending for patients hospitalized in the Internal
Medicine ward, Supervisor in charge at the Emergency Department and at the
Infectious Diseases Outpatient Clinic, Infectious Diseases Consultant for
hospitalised patients
February 2005-August 2009:
Lecturer in Internal Medicine and Infectious Diseases at 4th Dpt of Internal
Medicine, initially at “Sismanoglion” General Hospital, Athens, Greece and
later at University General Hospital “Attikon”
Main responsibilities: as above. Teaching 4th -year and 6th -year medical
students, residents and fellows
August 2009-present:
Assistant Professor in Internal Medicine and Infectious Diseases at 4th Dpt of
Internal Medicine, University General Hospital “Attikon”
Main responsibilities: as above. Organizing and supervising several research
teams working in the field of antimicrobial resistance and for the surveillance,
prevention and control of health-care associated infections, leading member
of teams that produced national guidelines for rational use of antibiotics for
out- and inpatients, Auditing for compliance with the antibiotic stewardship
program in the hospital
4. Teaching Experience
1994 to present: Participated in training of 4th -year medical students in
Athens University School of Medicine
1999 to present: Participated in training of 6th -year medical students, of
Residents in Internal Medicine and of Fellows in Infectious Diseases in Athens
University School of Medicine
2004- 2010: Coordinator of the Educational Program of Residents in Internal
Medicine in the 4th Dpt of Internal Medicine, Athens University School of
Medicine
2010-2011: Coordinator of the 6-month course on “Internal Medicine” for the
3rd -year students in the School of Dentistry, Athens University School of
Medicine
2010 to present: Coordinator of the Educational Program of 6th -year medical
students at 4th Dpt of Internal Medicine, Athens University School of Medicine
Participated as an invited speaker in more than 80 workshops, seminars and
post-graduate courses in the field of Internal Medicine and Infectious
Diseases
Supervisor for 13 PhD Theses in the field of Infectious Diseases in Athens
University School of Medicine
Principal Investigator in several clinical trials
5. Research Activities
Her research interests include:
In vitro antimicrobial activity and interactions of antimicrobial agents against
various Gram-positive and Gram-negative microorganisms
In vivo efficacy of antimicrobials in experimental models of infections
(endocarditis and intraperitoneal abscess models)
Molecular mechanisms of resistance of Gram-negative and Gram-positive
microorganisms against various antimicrobials
Outbreak investigations
She is the Leading Scientist at the Molecular Biology Section of the Infectious
Diseases Research Laboratory, 4th Dpt of Internal Medicine, University
General Hospital “Attikon”
6. Honors
She has been awarded 11 honorary awards for her research activities
7. Member
Hellenic Society for Chemotherapy
Hellenic Society of Infectious Diseases
National Antibiogram Committee
ESCMID Study Group for Antimicrobial Resistance Surveillance (ESGARS)
ESCMID Education Subcommittee
8. Publications
Author or coauthor in more than 25 chapters in Medical Books
Publications in peer-reviewed medical journals:
1. Giamarellou H, Souli M, Antoniadou A, Gogas J. Periareolar
nonpuerperal breast infection: Treatment of 38 Cases. Clin Infect Dis 1994;
18:73-6
2. Souli M, Giamarellou H. Effects of slime produced by clinical isolates of
coagulase-negative Staphylococci on activities of various antimicrobial
agents. Antimicrob Agents Chemother 1998; 42:939-41
3. Eliopoulos GM, Wennersten CB, Gold HS, Schulin T,Souli M, Farris
MG, Cerwinka S, Nadler HL, Dowzicky M, Talbot GH, Moellering RC, Jr.
Characterization of vancomycin-resistant Enterococcus faecium isolates
from the United States and their susceptibility in vitro to DalfopristinQuinupristin. Antimicrob Agents Chemother 1998; 42:1088-92
4. Souli M, Wennersten CB, Eliopoulos GM. In vitro activity of BAY 128039, a new fluoroquinolone, against species representative of respiratory
tract pathogens. Int J Antimicrob Agents 1998; 10:23-30
5. Souli M, Thauvin-Eliopoulos C, Moellering RC, Jr., Eliopoulos GM. In
vivo activity of Evernimicin (SCH 27899) against vancomycin-susceptible
and vancomycin-resistant Enterococci in experimental endocarditis.
Antimicrob Agents Chemother, 2000; 44:2733-9
6. Torres-Viera C, Thauvin-Eliopoulos C, Souli M, DeGirolami P, Farris
MG, Wennersten CB, Sofia RD, Eliopoulos GM. Activities of Taurolidine in
vitro and in experimental enterococcal endocarditis. Antimicrob Agents
Chemother, 2000; 44:1720-4
7. Souli M, Kopsinis G, Kavouklis E, Gabriel L, Giamarellou H.
Vancomycin levels in human aqueous humour after intravenous and
subconjunctival administration. Int J Antimicrob Agents, 2001; 18:239-43
8. Galani I, Souli M, Chryssouli Z, Katsala D, Giamarellou H. First
identification of an Escherichia coli clinical isolate producing both metallobeta-lactamase VIM-2 and extended-spectrum beta-lactamase IBC-1. Clin
Microbiol Infect 2004; 10:757-60
9. Galani I, Souli M, Chryssouli Z, Orlandou K, Giamarellou H.
Characterization of a new integron containing blaVIM-1 and aac(6’)-IIc in an
Enterobacter cloacae clinical isolate from Greece. J Antimicrob Chemother
2005; 55: 634–8
10. Souli M, Pontikis K, Chryssouli Z, Galani I, Orlandou K, Katsala D,
Giamarellou H. Successful treatment of right-sided prosthetic valve
endocarditis due to methicillin-resistant teicoplanin-heteroresistant
Staphylococcus aureus with linezolid. Eur J Clin Microbiol Infect Dis 2005;
24:760-2
11. Galani I, Souli M, Koratzanis E, Chryssouli Z, Giamarellou H.
Molecular characterization of an Escherichia coli clinical isolate that
produces both metallo-beta-lactamase VIM-2 and extended-spectrum-betalactamase GES-7: identification of the In8 integron carrying the blaVIM-2
gene. J Antimicrob Chemother 2006; 58:432–3
12. Souli M, Kontopidou F, Koratzanis E, Antoniadou A, Giannistioti E,
Evangelopoulou P, Kannavaki S, Giamarellou H. In vitro activity of
tigecycline against multiple-drug-resistant, including pan-resistant, gram-
negative and gram-positive clinical isolates from Greek hospitals.
Antimicrob Agents Chemother2006; 50:3166-9
13. Volonakis K, Souli M, Kapaskelis A, Baziaka F, Grammelis V, Ziakas
PD, Giamarellou H. Evolution of resistance patterns and identification of
risk factors for Streptococcus pneumoniae colonisation in daycare centre
attendees in Athens, Greece. Int J Antimicrob Agents 2006; 28:297-301
14. Souli M, Volonakis K, Kapaskelis A, Galani I, Grammelis V, Vorou FR,
Tsivra M, Chryssouli Z, Katsala D and Giamarellou H. Characterisation of
macrolide-non-susceptible Streptococcus pneumoniae colonising children
attending day-care centres in Athens, Greece during 2000 and 2003. Clin
Microbiol Infect 2007; 13:70-7.
15. Cornaglia G, Akova M, Amicosante G, Canton R, Cauda R, Docquier
JD, Edelstein M, Frere JM, Fuzi M, Galleni M, Giamarellou H, Gniadkowski
M, Koncan R, Libisch B, Luzzaro B, Miriagou V, Navarro F, Nordmann P,
Pagani L, Peixe L, Poirel L, Souli M, Tacconelli E, Vatopoulos A, Rossolini
GM: ESCMID Study Group for Antimicrobial Resistance Surveillance
(ESGARS). Metallo-beta-lactamases as emerging resistance determinants
in Gram-negative pathogens: open issues. Int J Antimicrob Agents 2007;
29:380-8
16. Galani I, Souli M, Chryssouli Z, Giamarellou H. Detection of CTX-M-15
and CTX-M-33, a novel variant of CTX-M-15, in clinical Escherichia coli
isolates in Greece. Int J Antimicrob Agents 2007; 29: 598-600
17. Galani I, Souli M, Koratzanis E, Koratzanis G, Chryssouli Z and
Giamarellou H. Emerging bacterial pathogens: Escherichia coli,
Enterobacter aerogenes and Proteus mirabilis clinical isolates harbouring
the same transferable plasmid coding for metallo-β-lactamase VIM-1 in
Greece. J Antimicrob Chemother 2007; 59:578-9
18. Antoniadou A, Kontopidou F, Poulakou G, Koratzanis E, Galani I,
Papadomichelakis E, Kopterides P, Souli M, Armaganidis A, Giamarellou
H. Colistin-resistant isolates of Klebsiella pneumoniae emerging in
intensive care unit patients: first report of a multiclonal cluster. J Antimicrob
Chemother 2007; 59:786-90
19. Sakka V, Tsiodras S, Galani L, Antoniadou A, Souli M, Galani I,
Pantelaki M, Siafakas N, Zerva L, Giamarellou H. Risk-factors and
predictors of mortality in patients colonised with vancomycin-resistant
enterococci. Clin Microbiol Infect 2008; 14:14-21
20. Galani I, Rekatsina PD, Hatzaki D, Plachouras D, Souli M and
Giamarellou H. Evaluation of different laboratory tests for the detection of
metallo-β-lactamase production in Enterobacteriaceae. J Antimicrob
Chemother 2008, 61: 548-53
21. Souli M, Kontopidou F, Papadomichelakis E, Galani I, Armaganidis A,
Giamarellou H. Clinical experience of serious infections caused by
Enterobacteriaceae producing VIM-1 metallo-β-lactamase in a Greek
University Hospital. Clin Infect Dis 2008, 46: 847-54.
22. Galani I, Kontopidou F, Souli M, Rekatsina PD, Koratzanis E,
Deliolanis J, Giamarellou H. Colistin susceptibility testing by E-test and
disk diffusion methods. Int J Antimicrob Agents 2008; 31:434-9
23. Souli M, Sakka V, Galani I, Antoniadou A, Galani L, Siafakas N, Zerva
L, Fytrou H, Tsiodras S, Giamarellou H. Colonization with vancomycin and
linezolid-resistant Enterococcus faecium in a University Hospital: molecular
epidemiology and risk factor analysis. Int J Antimicrob Agents 2009;
33:137-42
24. Souli M, Rekatsina PD, Chryssouli Z, Galani I, Giamarellou H,
Kanellakopoulou K. Does the activity of the combination of imipenem and
colistin in vitro exceed the problem of resistance against metallo-βlactamase producing Klebsiella pneumoniae isolates? Antimicrob Agents
Chemother 2009; 53:2133-5
25. Souli M, Galani I, Giamarellou H. Emergence of extensively drugresistant and pandrug-resistant Gram-negative bacilli in Europe.
Eurosurveillance; 2008 Nov 20;13(47). pii: 19045
26. Souli M, Galani I, Antoniadou A, Papadomichelakis E, Poulakou G,
Panagea T, Vourli S, Zerva L, Armaganidis A, Kanellakopoulou K,
Giamarellou H.An outbreak of infection due to beta-lactamase Klebsiella
pneumoniae carbapenemase -2-producing K.pneumoniae in a Greek
University Hospital: molecular characterization, epidemiology and
outcomes. Clin Infect Dis 2010; 50:364-73
27. Carmeli Y, Akova M, Cornaglia G, Daikos GL, Garau J, Harbarth S,
Rossolini GM, Souli M, Giamarellou H. Controlling the spread of
carbapenemase-producing Gram-negatives: therapeutic approach and
infection control. Clin Micriobiol Infect 2010; 16:102-11
28. Fakas M, Souli M, Koratzanis G, Karageorgiou C, Giamarellou H,
Kanellakopoulou K. Effects of antimicrobial prophylaxis on asymptomatic
bacteriuria and predictors of failure in patients with multiple sclerosis. J
Chemother 2010;22: 36-43.
29. Souli M, Giannitsioti E, Chryssouli Z, Galani I, Panagea T,
Kanellakopoulou K, Giamarellou H. Contemporary trends in susceptibilities
to older and new antimicrobial agents of clinical Staphylococcus aureus
isolates from a Greek University Hospital. Int J Antimicrob Agents 2010;
36:187-9.
30. Gogos C, Kotsaki A, Pelekanou A, Giannikopoulos G, Vaki I, Maravitsa
P, Adamis S, Alexiou Z, Andrianopoulos G, Antonopoulou A, Athanassia S,
Baziaka F, Charalambous A, Christodoulou S, Dimopoulou I, Floros I,
Giannitsioti E, Gkanas P, Ioakeimidou A, Kanellakopoulou K, Karabela N,
Karagianni V, Katsarolis I, Kontopithari G, Kopterides P, Koutelidakis I,
Koutoukas P, Kranidioti H, Lignos M, Louis K, Lymberopoulou K, Mainas E,
Marioli A, Massouras C, Mavrou I, Mpalla M, Michalia M, Mylona H, Mytas
V, Papanikolaou I, Papanikolaou K, Patrani M, Perdios I, Plachouras D,
Pistiki A, Protopapas K, Rigaki K, Sakka V, Sartzi M, Skouras V, Souli M,
Spyridaki A, Strouvalis I, Tsaganos T, Zografos G, Mandragos K, KlouvaMolyvdas P, Maggina N, Giamarellou H, Armaganidis A, GiamarellosBourboulis EJ. Early alterations of the innate and adaptive immune
statuses in sepsis according to the type of underlying infection. Crit Care
2010 May 26;14(3):R96.
31. Galani I, Souli M, Mitchell N, Chryssouli Z, Giamarellou H. Presence of
plasmid-mediated quinolone resistance in Klebsiella pneumoniae and
Escherichia coli isolates possessing blaVIM-1 in Greece. Int J Antimicrob
Agents 2010; 36:252-4
32. Masgala A, Galani I, Souli M, Giamarellou H. Discrepancies between
various methods in susceptibility testing and epidemiological analysis of
Stenotrophomonas maltophilia clinical isolates. Cent Eur J Public Health
2010; 18:119-23
33. Souli M. Present and emerging therapies for the treatment of drugresistant infections: Focus on Linezolid. Clinl Med Reviews Ther 2010; 2:120
34. Panagea T, Galani I, Souli M, Adamou P, Antoniadou A, Giamarellou
H. Evaluation of CHROMagar KPC for the detection of carbapenemaseproducing Enterobacteriaceae in rectal surveillance cultures. Int J
Antimicrob Agents 2011;37:124-8
35. Souli M, Konstantinidou E, Tzepi I, Tsaganos T, Pefanis A, Chryssouli
Z, Galani I, Giamarellos-Bourboulis E, Giamarellou H. Efficacy of
carbapenems against a metallo-β-lactamase-producing Escherichia coli
clinical isolate in a rabbit intra-abdominal abscess model. J Antimicrob
Chemother 2011; 66:611-7
36. Souli M, Galani I, Boukovalas S, Gourgoulis MG, Chryssouli Z,
Kanellakopoulou K, Panagea T, Giamarellou H. In vitro interactions of
antimicrobial combinations with fosfomycin against KPC-2 producing
Klebsiella pneumoniae and protection of resistance development.
Antimicrob Agents Chemother. 2011;55:2395-7.
37. Kontopidou F, Galani I, Panagea T, Antoniadou A, Souli M,
Paramythiotou E, Koukos G, Karadani I, Armaganidis A, Giamarellou H.
Comparison of direct antimicrobial susceptibility testing methods for rapid
analysis of bronchial secretion samples in ventilator-associated pneumonia.
Int J Antimicrob Agents. 2011;38:130-4.
38. Panagea T, Galani I, Souli M, Karantani I, Giamarellou H, Petrikkos G.
Glycopeptide and daptomycin susceptibility and vancomycin
heteroresistance of methicillin-resistant Staphylococcus aureus clinical
isolates from a Greek University Hospital. Int J Antimicrob Agents. 2011;
38:451-2.
39. Koratzanis E, Souli M, Galani I, Chryssouli Z, Armaganidis A,
Giamarellou H. Epidemiology and molecular characterization of metallo-βlactamase producing Enterobacteriaceae in a university hospital Intensive
Care Unit in Greece. Int J Antimicrob Agents. 2011; 38:390-7.
40. Galani I, Souli M, Panagea T, Poulakou G, Kanellakopoulou K,
Giamarellou H. Prevalence of 16SrRNA methylase genes in
Enterobacteriaceae isolates from a Greek university hospital. Clin Microbiol
Infect. 2012; 18:E52-4
41. Lampri N, Galani I, Poulakou G, Katsarolis I, Petrikkos G, Giamarellou
H, Souli M. Mecillinam/clavulanate combination: a possible option for the
treatment of community-acquired uncomplicated urinary tract infections
caused by extended-spectrum β-lactamase-producing Escherichia coli. J
Antimicrob Chemother. 2012; 67:2424-8
42. Hatzaki D, Poulakou G, Katsarolis I, Lambri N, Souli M, Deliolanis I,
Nikolopoulos GK, Lebessi E, Giamarellou H. Cefditoren: Comparative
efficacy with other antimicrobials and risk factors for resistance in clinical
isolates causing UTIs in outpatients. BMC Infect Dis. 2012 Sep
25;12(1):228
43. Galani I, Souli M, Daikos GL, Chrysouli Z, Poulakou G, Psichogiou M,
Panagea T, Argyropoulou A, Stefanou I, Plakias G, Giamarellou H,
Petrikkos G. Activity of Plazomicin (ACHN-490) against MDR clinical
isolates of Klebsiella pneumoniae, Escherichia coli, and Enterobacter spp.
from Athens, Greece. J Chemother. 2012; 24:191-4
44. Daikos GL, Markogiannakis A, Souli M, Tzouvelekis LS.
Bloodstream infections caused by carbapenemase-producing
Klebsiella pneumoniae: a clinical perspective. Expert Rev Anti Infect
Ther 2012; 10:1393-404
45. Souli M, Galani I, Plachouras D, Panagea T, Armaganidis A, Petrikkos
G, Giamarellou H. Antimicrobial activity of copper surfaces against
carbapenemase-producing contemporary Gram-negative clinical isolates. J
Antimicrob Chemother 2013; 68:852-7
46. Antoniadou A, Kanellakopoulou K, Kanellopoulou M, Polemis M,
Koratzanis G, Papademetriou E, Poulakou G, Giannitsioti E, Souli M,
Vatopoulos A, Giamarellou H. Impact of a hospital-wide antibiotic restriction
policy program on the resistance rates of nosocomial Gram-negative
bacteria. Scand J Infect Dis 2013; 45:438-45
47. Plachouras D, Antoniadou A, Giannitsioti E, Galani E, Katsarolis I,
Kavatha D, Koukos G, Panagopoulos P, Papadopoulos A, Poulakou G,
Sakka V, Souli M, Sympardi S, Tsiodras S, Kanellakopoulou K, Giamarellou
H. Promoting prudent use of antibiotics: the experience from a multifaceted
regional campaign in Greece. BMC Public Health 2014 [accepted]
Galani I, Panagea T, Chryssouli Z, Giamarellou H, Souli M. In vivo
transmission of a plasmid containing the KPC-2 gene in a single patient. J
Global Antimicrob Res 2013; [Epub ahead of print]
48. Lamprini G, Galani I, Souli M, Karaiskos I, Katsouda E, Patrozou H,
Baziaka F, Paskalis C, Giamarellou H. Nosocomial dissemination of
Providencia stuartii isolates producing extended-spectrum
b-lactamases VEB-1 and SHV-5, metallo-b-lactamase VIM-1, and RNA
methylase RmtB. J Global Antimicrob Res 2013; 1:115-116
49. Galani I, Orlandou K, Moraitou H, Petrikkos G, Souli M. Colistin/
daptomycin: an unconventional antimicrobial combination synergistic in vitro
against multidrug-resistant Acinetobacter baumannii. Int J Antimicrob Agents
2014 Feb 4. pii: S0924-8579(14)00019-3. doi:
10.1016/j.ijantimicag.2013.12.010. [Epub ahead of print]
9. Submissions of Gene Sequences at GenBank Database
(http://www.ncbi.nlm.gov)
1. I.Galani, M.Souli, H.Giamarellou. CTX-M-33, Plasmid-mediated extendedspectrum beta-lactamase (CTX-M-15 like) from Greece. Escherichia coli
plasmid pGR2439 CTX-M-33 beta-lactamase (bla) gene, complete cds.
GenBank Accession Number AY 238472, February 2003.
http://www.ncbi.nlm.gov
2. I.Galani, M.Souli, Z.Chrysouli, D. Katsala, H.Giamarellou. First
identification of an Escherichia coli clinical isolate producing both metallobeta-lactamase VIM-2 and extended-spectrum beta-lactamase IBC-1
Escherichia coli class 1 integron integrase (intI1) gene, partial cds, and
metallo-beta-lactamase (blaVIM-2) gene, complete cds. GenBank
Accession Number AY781413, October 2004. http://www.ncbi.nlm.gov
3. I.Galani, M.Souli, Z.Chryssouli, K.Orlandou. H.Giamarellou.
Characterization of a new integron containing blaVIM-1 and aac(6')-IIc in
an Enterobacter cloacae clinical isolate from Greece. Enterobacter
cloacae transposon class 1 integron Int87 integrase (intI1) gene, partial
cds, and metallo-beta-lactamase (blaVIM-1) and aminoglycoside 6'-Nacetyltransferase (aac(6')-IIc) genes, complete cds. GenBank Accession
Number AY648125, June 2005. http://www.ncbi.nlm.gov
4. Galani I., Souli M., Koratzanis E., Koratzanis G., Chryssouli Z.
Giamarellou H. Emerging bacterial pathogens: Escherichia coli,
Enterobacter aerogenes and Proteus mirabilis clinical isolates harbouring
the same transferable plasmid coding for metallo-beta-lactamase VIM-1in
Greece. Proteus mirabilis class I integron In73, partial sequence. GenBank
Accession Number EF093146, October 2006. http://www.ncbi.nlm.gov
5. Galani I., Souli M., Koratzanis E., Koratzanis G., Chryssouli Z.
Giamarellou H. Emerging bacterial pathogens: Escherichia coli,
Enterobacter aerogenes and Proteus mirabilis clinical isolates harbouring
the same transferable plasmid coding for metallo-beta-lactamase VIM-1in
Greece. Escherichia coli class I integron IntI1 (intI1) gene, partial cds, and
metallo-beta-lactamase VIM-1 (blaVIM-1), DhfrI (dhfrI), and ANT(3')-Ia
(aadA1) genes, complete cds. GenBank Accession Number EF078697,
October 2006. http://www.ncbi.nlm.gov
6. Galani I., Souli M., Koratzanis E., Koratzanis G., Chryssouli Z.
Giamarellou H. Emerging bacterial pathogens: Escherichia coli,
Enterobacter aerogenes and Proteus mirabilis clinical isolates harbouring
the same transferable plasmid coding for metallo-beta-lactamase VIM-1in
Greece. Enterobacter aerogenes class I integron In1159, partial sequence.
GenBank Accession Number EF093145, October 2006.
http://www.ncbi.nlm.gov
7. I.Galani, M.Souli, H.Giamarellou. Proteus mirabilis insertion sequence
ISEcp1 transposase (tnpA) gene, complete cds; and class C betalactamase (blaCMY-14) gene, complete cds. GenBank Accession Number
EU600193, March 2008. http://www.ncbi.nlm.gov